Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 16, 2006

Tris Pharma Expands Facilities

  • Tris Pharma unveiled a new research and manufacturing facility at its South Brunswick, NJ campus. The 30,000-sq-ft expansion adds a cGMP facility.

    “This facility enhances our manufacturing capabilities and also enables us to continue to invest in our drug development,” says Ketan Mehta, CEO and founder. “This is the final piece of the puzzle for our first phase of growth and keeps our operations scalable to keep pace with several more deals and new technologies in the pipeline.”

    The company reports that it can now provide its partners clinical supplies, submission batches, eCTD filing, and medium-scale commercial production of tablets, capsules, liquid suspensions, and oral solutions, and packaging for the finished products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »